Lasmiditan — Membership Pricing

Other medications in Neurological

• Meclizine
• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)
• Nusinersen
• Ocrelizumab
• Ofatumumab
• Oxcarbazepine

About Lasmiditan

Lasmiditan, known by its brand name Reyvow, represents a significant advancement in acute migraine treatment, offering a unique mechanism of action. For individuals enduring the debilitating impact of migraines, accessing effective medication is paramount. TheDrugClub is committed to empowering members by helping them navigate the costs of essential prescriptions like lasmiditan, ensuring more affordable access to vital care.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lasmiditan is approved for (FDA label)

REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.

Source: Read the full FDA label on DailyMed. Label effective date: January 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lasmiditan (FDA label)

REYVOW (lasmiditan) tablets are available in two strengths: 50 mg tablet: light gray, oval, film coated, tablets with “L-50” debossed on one side and “4312” on the other 100 mg tablet: light purple, oval, film coated, tablets with “L-100” debossed on one side and “4491” on the other Tablets: 50 mg, 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: aea3358c-ff41-4490-9e6d-c7bf7b3de13f. SPL document ID: 29f467c6-0365-4831-b4ce-9a0eefaf5896. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lasmiditan (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Driving Impairment [see Warnings and Precautions ( 5.1 )] Central Nervous System Depression [see Warnings and Precautions ( 5.2 )] Serotonin Syndrome [see Warnings and Precautions ( 5.3 )] Medication Overuse Headache [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (≥5% and > placebo) were dizziness, fatigue, paresthesia, and sedation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: aea3358c-ff41-4490-9e6d-c7bf7b3de13f. SPL document ID: 29f467c6-0365-4831-b4ce-9a0eefaf5896. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lasmiditan (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: aea3358c-ff41-4490-9e6d-c7bf7b3de13f. SPL document ID: 29f467c6-0365-4831-b4ce-9a0eefaf5896. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lasmiditan (FDA label)

Driving Impairment: Advise patients not to drive or operate machinery until at least 8 hours after taking each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW. ( 5.1 ) Central Nervous System (CNS) Depression: REYVOW may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS depressants. ( 5.2 , 7.1 ) Serotonin Syndrome: Reactions consistent with serotonin syndrome were reported in patients treated with REYVOW. Discontinue REYVOW if symptoms of serotonin syndrome occur. ( 5.3 ) Medication Overuse Headache: Detoxification may be necessary. ( 5.4 ) 5.1 Driving Impairment REYVOW may cause significant driving impairment.

Source: FDA prescribing information (DailyMed). Set ID: aea3358c-ff41-4490-9e6d-c7bf7b3de13f. SPL document ID: 29f467c6-0365-4831-b4ce-9a0eefaf5896. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lasmiditan (FDA label)

REYVOW may further lower heart rate when administered with heart rate lowering drugs. ( 7.3 ) 7.1 CNS Depressants Concomitant administration of REYVOW and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of REYVOW to cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants [see Warnings and Precautions ( 5.2 )] . 7.2 Serotonergic Drugs Concomitant administration of REYVOW and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St.

Source: FDA prescribing information (DailyMed). Set ID: aea3358c-ff41-4490-9e6d-c7bf7b3de13f. SPL document ID: 29f467c6-0365-4831-b4ce-9a0eefaf5896. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.